Sei Investments Co. Sells 33,861 Shares of Medpace Holdings, Inc. $MEDP

Sei Investments Co. reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 37.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,421 shares of the company’s stock after selling 33,861 shares during the period. Sei Investments Co.’s holdings in Medpace were worth $26,612,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in MEDP. Allspring Global Investments Holdings LLC increased its position in Medpace by 164.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock valued at $2,086,000 after acquiring an additional 2,274 shares during the last quarter. Cerity Partners LLC raised its stake in shares of Medpace by 41.0% in the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock valued at $45,478,000 after acquiring an additional 23,530 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Medpace by 24,930.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock worth $56,936,000 after acquiring an additional 100,968 shares during the last quarter. UBS Group AG lifted its holdings in shares of Medpace by 32.8% in the 4th quarter. UBS Group AG now owns 328,879 shares of the company’s stock worth $184,715,000 after acquiring an additional 81,250 shares during the last quarter. Finally, Mitchell Capital Management Co. purchased a new position in shares of Medpace during the 4th quarter worth about $3,383,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Barclays set a $600.00 price target on shares of Medpace in a report on Thursday, July 23rd. Truist Financial boosted their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. BMO Capital Markets upped their target price on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday. Finally, Leerink Partners set a $620.00 price target on Medpace in a report on Thursday, July 23rd. Two research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $584.18.

Insider Buying and Selling at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 20.50% of the company’s stock.

Medpace Trading Down 3.1%

Shares of MEDP opened at $570.97 on Wednesday. The firm has a fifty day moving average price of $498.48 and a 200-day moving average price of $493.41. The firm has a market capitalization of $15.94 billion, a P/E ratio of 33.47, a P/E/G ratio of 2.63 and a beta of 1.15. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter last year, the firm posted $3.10 EPS. The firm’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.55 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.